Product Name:
NDR1-pS281+pT282
Product Number:
ab-pk731
Target Full Name: Serine/threonine-protein kinase 38
Target Alias: AA617404; DJ108K11.2; NDR1 protein kinase; NDR; STK38; CCDS4822.1; ENSG00000112079
Product Type Specific: NDR1 protein kinase phosphosite-specific antibody
Antibody Code: PK731
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S281+T282
Protein UniProt: Q15208
Protein SigNET: NDR1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human NDR1 (NDR, STK38) sequence peptide Cat. No.: PE-04AOD99
Antibody Immunogen Sequence: LAF(pS)(pT)VGT(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues L278 to T285; in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S2478 and S2481 phosphorylation stimulate phosphotransferase activity. These are two of the major in vivo phosphorylation sites in mTOR (≥23 and ≥26 reports, respectively, from high throughput mass spectrometry studies recorded in PhosphoSitePlus). mTOR is known to be phosphorylated in vitro at S2478 by mTOR (FRAP1), and at S2481 by mTOR (FRAP1).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Medium immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Mouse | Chicken | Frog | Zebra fish | Fruit fly | Nematode worm | Budding yeast.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 52-57 kDa.
Related Product 1: NDR1 (278-285) pS281+pT282 antibody blocking peptide (Cat. No.: PE-04AOD99)
Scientific Background: NDR1 (STK38) is a protein-serine/threonine kinase of the AGC group and NDR family. It regulates essential cellular processes, including cell cycle progression (G/S transition), centrosome duplication, cell morphology, apoptosis, and neurodevelopment. It is activated by binding of S100B, which releases autoinhibitory N-lobe interactions, enabling ATP to bind and the autophosphorylation of Ser-281. Phosphorylation at Ser-281 increases phosphotransferase activity and interaction with co-activator MOB1. Thr-444 then undergoes calcium-dependent phosphorylation by an upstream kinases MST1 and MST2. Interactions between phosphorylated Thr-444 and the N-lobe promote additional structural changes that complete the activation of the kinase. Phosphorylation at Thr-74 induces interaction with S100B. Thr-444 then undergoes calcium-dependent phosphorylation by an upstream kinase. T74A, K118A, S281A, and T444A mutations are involved in decreased or loss of autophosphorylation and kinase activity. NDR1 is a negative regulator of MAP3K1/2 signalling. It converts MAP3K2 from its phosphorylated form to its nonphosphorylated form and inhibits autophosphorylation of MAP3K2. NDR1 is an important regulator of Myc's oncogenic activity in human B-cell lymphomas. It features an N-terminal S100B/calmodulin binding site and a catalytic kinase domain, with 85% similarity to the NDR2 isoform. Widely expressed, NDR1 dysregulation is linked to tumor progression (e.g., breast/prostate cancer), and it acts as a modulator of Hippo pathway signalling. Its activation of the MAPK/ERK pathway has been implicated in oncogenesis as either a promoter or inhibitor depending on the cancer system. It promotes viral and bacterial defense by enhancing type I interferon production, yet its downregulation is associated with immune evasion in some infections. This description may include information annotated by UniProt and/or Google AI.